Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Research & Development (2017 - 2026)

Lexaria Bioscience's Research & Development history spans 10 years, with the latest figure at $475388.0 for Q1 2026.

  • Quarterly results put Research & Development at $475388.0 for Q1 2026, down 71.8% from a year ago — trailing twelve months through Feb 2026 was $5.7 million (up 10.95% YoY), and the annual figure for FY2025 was $8.2 million, up 249.02%.
  • Research & Development for Q1 2026 was $475388.0 at Lexaria Bioscience, down from $671340.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $2.7 million in Q2 2025 to a low of $245779.0 in Q1 2024.
  • The 5-year median for Research & Development is $696178.0 (2023), against an average of $988043.5.
  • The sharpest move saw Research & Development skyrocketed 585.95% in 2025, then plummeted 71.8% in 2026.
  • Year by year, Research & Development stood at $829489.0 in 2022, then tumbled by 30.74% to $574491.0 in 2023, then soared by 239.99% to $2.0 million in 2024, then crashed by 65.63% to $671340.0 in 2025, then fell by 29.19% to $475388.0 in 2026.
  • According to Business Quant data, Research & Development over the past three periods came in at $475388.0, $671340.0, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.